本文選題：鼻咽癌 + 扶正清鼻方　； 參考：《中國(guó)實(shí)驗(yàn)方劑學(xué)雜志》2014年13期

【摘要】：目的:探討扶正清鼻方輔助放療治療鼻咽癌(NPC)放射性口腔黏膜損傷及對(duì)血漿脫氧核糖核酸(EBV-DNA),血清EB病毒衣殼抗原抗體(VCA-IgA)和早期抗原抗體(EA-IgA)的影響。方法:將80例NPC患者隨機(jī)按入診前后順序分為對(duì)照組和觀察組各40例。對(duì)照組進(jìn)行放療+對(duì)癥支持治療。觀察組在對(duì)照組治療的基礎(chǔ)上加服扶正清鼻方,1劑/d。兩組療程均為12周。觀察放射性口腔黏膜損傷出現(xiàn)時(shí)間及程度,于第3,7周進(jìn)行生活質(zhì)量評(píng)分;采用聚合酶鏈?zhǔn)椒磻?yīng)法(PCR)檢測(cè)血漿EBV-DNA水平;采用酶聯(lián)免疫吸附劑測(cè)定(ELISA)檢測(cè)血清VCA-IgA和EA-IgA水平。結(jié)果:治療后第3周,觀察組放射性口腔黏膜損傷Ⅲ級(jí)反應(yīng)發(fā)生率為40%,對(duì)照組為57.5%,差異無統(tǒng)計(jì)學(xué)意義;觀察組Ⅳ級(jí)反應(yīng)發(fā)生率為2.5%,對(duì)照組為17.5%,差異有統(tǒng)計(jì)學(xué)意義(P0.05);治療后第7周,觀察組Ⅲ級(jí)反應(yīng)發(fā)生率為55%,對(duì)照組為70%;治療組Ⅳ級(jí)反應(yīng)發(fā)生率為7.5%,對(duì)照組為25%,差異有統(tǒng)計(jì)學(xué)意義(P0.05);對(duì)照組出現(xiàn)放射性口腔黏膜反應(yīng)時(shí)間為(18.5±2.8)d,觀察組為(15.5±2.7)d,觀察組晚于對(duì)照組(P0.01);治療后觀察組血漿EBV-DNA水平低于對(duì)照組(P0.01);治療后觀察組血清VCA-IgA和EA-IgA水平低于對(duì)照組(P0.01)。結(jié)論:扶正清鼻方能減輕鼻咽癌放射性口腔黏膜損傷,并能抑制咽癌血清EB病毒,降低血清病毒抗體水平,這可能對(duì)NPC復(fù)發(fā)或轉(zhuǎn)移抑制作用。
[Abstract]:Objective: to investigate the effects of Fuzheng Qingbifang (FQB) in the treatment of oral mucosal injury of nasopharyngeal carcinoma (NPC) and its effects on plasma DNA EBV-DNA, serum EB virus capsid antigen antibody (VCA-IgA) and early antigen antibody (EA-IgA). Methods: 80 patients with NPC were randomly divided into control group (n = 40) and observation group (n = 40). The control group was treated with radiotherapy and symptomatic support therapy. Observation group on the basis of the treatment of the control group plus Fuzheng Qingbei prescription 1 / d. The course of treatment was 12 weeks in both groups. To observe the time and degree of radiation oral mucosal injury, the quality of life (QOL) score was evaluated at the 3rd week, the plasma EBV-DNA level was detected by polymerase chain reaction (PCR), and the serum VCA-IgA and EA-IgA levels were detected by enzyme linked immunosorbent assay (Elisa). Results: at the 3rd week after treatment, the incidence of grade 鈪，

本文編號(hào)：1791918